Anteris Technologies Global Corp (ASX: AVR) Reports Q1 2025 Results
Anteris Technologies Global Corp (ASX: AVR) reports a 27% decline in Q1 sales and a 22% increase in operating loss, emphasizing strategic developments.
Category: Healthcare
Optiscan Imaging Ltd (ASX:OIL) Advances Robotic Surgery Collaboration with Mayo Clinic
Optiscan Imaging Ltd (ASX:OIL) advances its collaboration with Mayo Clinic to develop advanced imaging systems for robotic surgery.
Wellnex Life Limited (ASX:WNX) Reports 46% Revenue Growth and AIM Listing
Wellnex Life Limited (ASX:WNX) reports a 46% revenue increase for Q1 2025 and completes AIM Market listing to strengthen its financial position.
MedAdvisor Limited (ASX:MDR) Provides Strategic Review Update
MedAdvisor Limited (ASX:MDR) announces a strategic review update, detailing a potential $35 million sale of its ANZ business division to a major software firm.
Orthocell Limited (ASX:OCC) Accelerates US Remplir™ Sales Rollout with 12 Distributors
Orthocell Limited (ASX:OCC) accelerates Remplir™ sales rollout with 12 US distributors, surpassing targets and setting the stage for first sales.
Acrux Limited (ASX:ACR) Launches Dapsone 7.5% Gel in the United States
Acrux Limited (ASX:ACR) launches its differentiated Dapsone 7.5% Gel in the US, enhancing its prescription acne treatment portfolio.
LTR Pharma Limited (ASX:LTP) Signs Collaborative Agreement for OROFLOW® Development
LTR Pharma (ASX:LTP) collaborates with SDS to develop OROFLOW®, a novel intranasal spray for Oesophageal Motility Disorders.
Algorae Pharmaceuticals (ASX:1AI) Partners with Peter MacCallum Cancer Centre for AI-Driven Drug Screening
Algorae Pharmaceuticals (ASX:1AI) partners with Peter MacCallum Cancer Centre to validate AI-driven drug synergies in oncology.
Pro Medicus Limited (ASX:PME) Signs A$20M Contract with University of Iowa Health Care
Pro Medicus Limited (ASX:PME) signs a A$20M, 5-year contract with University of Iowa Health Care for its cloud-based Visage 7 platform.
Nyrada Inc. (ASX:NYR) Announces Positive Preclinical Study Results for NYR-BI03
Nyrada Inc. (ASX:NYR) reports significant cardioprotective findings for NYR-BI03 in preclinical studies, demonstrating potential for treating heart attack-related conditions.